Although tau PET has been hindered due to off-target binding of ligands to neuromelanin (Hansen et al., 2016) and MAO-B (Ng et al., 2017), both tracer classes can differentiate AD and non-AD tauopathy patients from healthy controls. The gene discussed is MAPT; the disease is Alzheimer disease.